Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037420 · ClinicalTrials.gov registry record · Phase 2
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
A Phase 2 study of Acromegaly, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT07037420: Recruiting Phase 2 study of Acromegaly, sponsored by Alexion Pharmaceuticals.
NCT07037420 is a Phase 2 study of Acromegaly that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 60 participants, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07037420, a Phase 2 study of Acromegaly, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN2420
Study Locations (20)
Other
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - Ciudad de Buenos Aires
- Research Site - Ciudad de Buenos Aires
- Research Site - Curitiba
- Research Site - Ribeirão Preto
- Research Site - Rio de Janeiro
- Research Site - São Paulo
- Research Site - Beijing
- Research Site - Guangzhou
- Research Site - Kunming
California
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Torrance
Colorado
- Research Site - Aurora
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Nevada
- Research Site - Las Vegas
New York
- Research Site - New York
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2027-11-11 |
| Phase | Phase 2 |
What NCT07037420 shows while recruiting
NCT07037420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037420 names 20 study sites across 8 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07037420 about?
NCT07037420 is a clinical study titled "ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly". The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
What is the current status of trial NCT07037420?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-28. Estimated completion is 2027-11-11.
What conditions does trial NCT07037420 study?
This clinical trial studies the following conditions: Acromegaly.
What interventions are being tested in trial NCT07037420?
The interventions under investigation include: Placebo (DRUG), ALXN2420 (DRUG).
Who is sponsoring clinical trial NCT07037420?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037420 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07037420's enrollment target sits among peer trials
60 8th of 13 higher than 6 of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
ACTIVE NOT RECRUITING · Phase 2
-
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI